Clinical study on Compound Xiatianwu Tablets combined with iguratimod in treatment of rheumatoid arthritis
Objective To explore the clinical efficacy of Compound Xiatianwu Tablets combined with iguratimod in treatment of rheumatoid arthritis. Methods Patients (106 cases) with rheumatoid arthritis in Wuhan Hospital of Traditional Chinese Medicine from February 2022 to February 2024 were randomly divided into control (53 cases) and treatment (53 cases) group. Patients in the control group were po administered with Iguratimod Tablets,25 mg/time,twice daily. Patients in the treatment group were po administered with Compound Xiatianwu Tablets on the basis of the control group,4 tablets/time,three times daily. Patients in two groups were treated for 10 weeks. After treatment,the clinical evaluations were evaluated,the scores of DAS-28 and VAS,the levels of CTX-Ⅱ,LTB4,SP,IL-1β,ESR,RF,CCP and CRP in two groups before and after treatment were compared. Results After treatment,the total effective rate in the treatment group was 96.23％ significantly higher than 83.02％ in the control group (P<0.05). After treatment,the DAS-28 scores and VAS scores in two groups were significantly lower than before treatment (P<0.05),and the scores in the treatment group were significantly lower than those in the control group (P<0.05). After treatment,the levels of CTX-Ⅱ,LTB4,SP,IL-1β,ESR,RF,CCP,and CRP in two groups were significantly reduced (P<0.05),and the levels of these indicators in the treatment group were significantly lower than those in the control group (P<0.05). Conclusion The combination of iguratimod and Compound Xiatianwu Tablets in treatment of patients with rheumatoid arthritis has a definite effect. It can improve joint swelling,pain and other symptoms,increase joint blood flow,and promote the joint to return to a stable state.
NETL
NSTL
万方数据
